Sun Pharma
QuietIndia's largest and world's fifth-largest specialty generics company
Company Overview
Sectors
Peer Comparison
Signal Timeline
2 totalDate unknown
Product LaunchCanonical—
Sun Pharma Announces US Availability of UNLOXCYT (cosibelimab-ipdl)
Sun Pharma announced that UNLOXCYT (cosibelimab-ipdl) is now available in the U.S. for the treatment of advanced cutaneous squamous cell carcinoma (aCSCC).
Regulatory & PolicyCanonical—
Sun Pharma receives DCGI approval for generic semaglutide
Sun Pharma has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide for the treatment of type 2 diabetes.
Get Sun Pharma signal updates
Get notified when new signals are published for this company.